Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopregnanolone in MCI and early Alzheimer's disease
NCT02221622Phase 1Completed
- Sponsor
- University of Southern California
- Start
- Aug 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of brexanolone in Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD) (4 arms), sponsored by University of Southern California. Primary endpoints: Adverse events at 16 weeks, Clinical laboratory measurements at 13 weeks and 3 more. Started Aug 2014; status: completed.
02
Drugs
brexanolone
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02221622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221622.